Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS)
CNY22.92
+0.22 (+0.97%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No.666 Jiangjun Road 465550
Xinyang, CN
Xinyang, CN
CEO
Wei Xiong
Website
lingrui.com
IPO
2000-10-18
ISIN CNE000001501
Description
Established in 1992 and headquartered in Xinyang, China, Henan Lingrui Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products throughout the Chinese market. The company offers a broad catalog of approximately 100 different medications, provided in ten distinct dosage formats such as adhesive plasters, tablets, capsules, granules, and tinctures. Prominent items in their product line include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY22.92
+0.22 (+0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.05
Float Shares
538.49M
Free Float %
95.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.89% | +4.10% | -0.58% | +1.82% | -1.41% | +7.97% | -3.62% | +25.90% | +129.33% | +114.79% | +603.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
22.92
DCF (Unlevered)
46.01
+100.7%
DCF (Levered)
49.20
+114.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.13
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.1% ★ Q1'26: +10.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+4.7% Q1'26: +12.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.0% Q1'26: +22.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.9% ★ Q1'26: +25.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+23.3% ★ Q1'26: +30.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.6% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.40× ★ Q1'26: 0.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.08B
est: 1.07B (+1.9%)
|
1.44B
est: 1.37B (+5.2%)
|
1.85B
est: 1.81B (+2.1%)
|
2.05B
est: 2.38B (-13.9%)
|
2.16B
est: 2.24B (-3.6%)
|
2.33B
est: 2.30B (+1.6%)
|
2.69B
est: 2.76B (-2.2%)
|
3.00B
est: 3.01B (-0.1%)
|
3.31B
est: 3.52B (-5.8%)
|
3.50B
est: 3.71B (-5.5%)
|
3.85B
est: 3.96B (-2.6%)
|
4.21B
4.21B – 4.21B
+6.6% YoY
|
4.56B
4.56B – 4.56B
+8.3% YoY
|
4.91B
4.91B – 4.91B
+7.6% YoY
|
| EBITDA |
173.16M
est: 194.58M (-11.0%)
|
215.28M
est: 249.93M (-13.9%)
|
297.43M
est: 330.82M (-10.1%)
|
362.46M
est: 435.73M (-16.8%)
|
396.26M
est: 408.81M (-3.1%)
|
384.66M
est: 419.30M (-8.3%)
|
447.63M
est: 503.34M (-11.1%)
|
463.40M
est: 549.20M (-15.6%)
|
664.74M
est: 1.05B (-37.0%)
|
795.48M
est: 1.11B (-28.4%)
|
981.94M
est: 1.19B (-17.2%)
|
1.26B
1.26B – 1.26B
+6.6% YoY
|
1.37B
1.37B – 1.37B
+8.3% YoY
|
1.47B
1.47B – 1.47B
+7.6% YoY
|
| EBIT |
136.08M
est: 168.18M (-19.1%)
|
172.29M
est: 216.03M (-20.2%)
|
247.21M
est: 285.93M (-13.5%)
|
294.07M
est: 376.62M (-21.9%)
|
328.69M
est: 353.35M (-7.0%)
|
316.20M
est: 362.41M (-12.8%)
|
376.45M
est: 435.05M (-13.5%)
|
389.07M
est: 474.69M (-18.0%)
|
588.93M
est: 1.01B (-41.9%)
|
723.74M
est: 1.07B (-32.3%)
|
883.37M
est: 1.14B (-22.5%)
|
1.21B
1.21B – 1.21B
+6.6% YoY
|
1.32B
1.32B – 1.32B
+8.3% YoY
|
1.42B
1.42B – 1.42B
+7.6% YoY
|
| Net Income |
131.91M
est: 135.37M (-2.6%)
|
345.77M
est: 349.71M (-1.1%)
|
217.11M
est: 219.98M (-1.3%)
|
243.26M
est: 270.75M (-10.2%)
|
294.44M
est: 304.59M (-3.3%)
|
325.49M
est: 315.87M (+3.0%)
|
361.54M
est: 383.56M (-5.7%)
|
465.30M
est: 456.88M (+1.8%)
|
568.11M
est: 666.60M (-14.8%)
|
722.55M
est: 699.37M (+3.3%)
|
759.50M
est: 837.74M (-9.3%)
|
841.32M
841.32M – 841.32M
+0.4% YoY
|
925.86M
925.86M – 925.86M
+10.0% YoY
|
1.02B
1.02B – 1.02B
+9.9% YoY
|
| SGA |
519.75M
est: 568.93M (-8.6%)
|
763.55M
est: 730.80M (+4.5%)
|
1.00B
est: 967.29M (+3.7%)
|
1.18B
est: 1.27B (-7.3%)
|
1.22B
est: 1.20B (+1.8%)
|
1.34B
est: 1.23B (+9.5%)
|
1.48B
est: 1.47B (+0.8%)
|
1.61B
est: 1.61B (+0.1%)
|
1.67B
est: 1.88B (-10.8%)
|
1.76B
est: 1.98B (-11.0%)
|
1.71B
est: 2.11B (-18.9%)
|
2.25B
2.25B – 2.25B
+6.6% YoY
|
2.44B
2.44B – 2.44B
+8.3% YoY
|
2.62B
2.62B – 2.62B
+7.6% YoY
|
| EPS |
0.25
est: 0.24 (+4.2%)
|
0.60
est: 0.62 (-3.2%)
|
0.37
est: 0.39 (-5.1%)
|
0.42
est: 0.48 (-12.5%)
|
0.52
est: 0.54 (-3.7%)
|
0.57
est: 0.56 (+2.4%)
|
0.66
est: 0.68 (-2.9%)
|
0.84
est: 0.81 (+3.7%)
|
1.01
est: 1.18 (-14.5%)
|
1.29
est: 1.24 (+4.0%)
|
1.34
est: 1.47 (-8.8%)
|
1.49
1.49 – 1.49
+1.5% YoY
|
1.64
1.64 – 1.64
+10.0% YoY
|
1.80
1.80 – 1.80
+9.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
803.83M
OE per share TTM
1.42
Owner's Yield
6.35%
Maintenance CapEx ratio
4.71%
Maint CapEx / Avg PPE
23.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.86% | 610.6K | 0.95% |
| 2 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.00% | 17.8K | 0.44% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 349.6K | 0.39% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 440.4K | 0.06% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 15.6K | 0.44% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 136.5K | 0.28% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 101.5K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.9K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.7K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.53M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
349.2K
Shares Outstanding
567.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guo Xin Feng | Secretary of the Board & Director | — | male |
| Hui Bin Wu | Deputy General Manager | — | male |
| Lei Li | Deputy General Manager | — | male |
| Peng Yu | Chief Financial Officer | — | male |
| Qiang Ye | Deputy General Manager | — | male |
| Wei Xiong | Chairman & GM | — | male |
| Xi Zhen Wu | Deputy GM & Director | — | male |
| Xiuying Hu | Accounting Supervisor | — | — |
| Yan Chen | Deputy GM & Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600285.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
